| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Ferroptosis inducer-13 (compound 4a) (72 hours) showed potent broad-spectrum anti-proliferative activity against cancer cells, with IC50 values of 2.11 μM (PC9), 2.17 μM (MDA-MB-231), 3.81 μM (SMMC-7721), and 4.10 μM (SGC-7901)[1]. Ferroptosis inducer-13 (0-40 μM; 24-72 hours) inhibited the proliferation of NSCLC cells (PC9 and H1975) in a dose- and time-dependent manner[1]. Ferroptosis inducer-13 (20 μM; 24 hours) induced ferroptosis in non-small cell lung cancer cells (PC9 and H1975)[1]. Ferroptosis inducer-13 (0-40 μM; 24 hours) leads to GSH depletion, increases Fe2+, ROS and LPO levels, and induces ferroptosis by modulating the Nrf2/xCT/GPX4 signaling pathway in PC9 and H1975 cells [1].
|
|---|---|
| ln Vivo |
Ferrocyte-13 (2 and 5 mg/kg; intraperitoneal injection; every 3 days for 18 days) inhibited tumor growth in a PC9 xenograft model and had good safety [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: PC9, H1975 Tested Concentrations: 0, 2.5, 5, 10, 20, 40 μM Incubation Duration: 24, 48, 72 h Experimental Results: Gradually decreased cell viability of PC9 and H1975 cells in a concentration manner. Exhibited significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner. Cell Viability Assay[1] Cell Types: PC9, H1975 Tested Concentrations: 20 μM Incubation Duration: 12 h Experimental Results: Significantly enhanced cell viability by approximately 20% when combined with ferroptosis inhibitor. Immunofluorescence[1] Cell Types: PC9, H1975 Tested Concentrations: 20 μM Incubation Duration: 24 h Experimental Results: Moderately reversed the GPX expression when combined with ferroptosis inhibitor. Western Blot Analysis[1] Cell Types: PC9, H1975 Tested Concentrations: 0, 5, 10, 20, 40 μM Incubation Duration: 24 h Experimental Results: Significantly decreased Nrf2 levels in both cytoplasmic and nuclear fractions while reducing xCT and GPX4 expression. |
| Animal Protocol |
Animal/Disease Models: Female Balb/c nude mice (16-20 g) subcutaneously injected with PC9 cells[1]
Doses: 2, 5 mg/kg Route of Administration: i.p.; every 3 days for 18 days Experimental Results: Exhibited tumor growth suppression with minimal impact on body weight. Caused no significant organ toxicity in mice. Significantly downregulated the protein expression of xCT and GPX4 in tumor tissues compared with the control group. |
| References |
| Molecular Formula |
C21H23NO3
|
|---|---|
| Molecular Weight |
337.41
|
| CAS # |
3085517-19-4
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9638 mL | 14.8188 mL | 29.6375 mL | |
| 5 mM | 0.5928 mL | 2.9638 mL | 5.9275 mL | |
| 10 mM | 0.2964 mL | 1.4819 mL | 2.9638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
